Expression of D2RmRNA isoforms and ERmRNA isoforms in prolactinomas: correlation with the response to bromocriptine and with tumor biological behavior-Reference-Cited by-同舟云学术

Expression of D2RmRNA isoforms and ERmRNA isoforms in prolactinomas: correlation with the response to bromocriptine and with tumor biological behavior

Published:2010-01-09 Issue:1 Volume:99 Page:25-32
ISSN:0167-594X
Container-title:Journal of Neuro-Oncology
language:en
Short-container-title:J Neurooncol

Author:

Wu Zhe Bao,Zheng Wei Ming,Su Zhi Peng,Chen Yong,Wu Jin Sen,Wang Cheng De,Lin Chen,Zeng Yan Jun,Zhuge Qi Chuan

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Neurology (clinical),Neurology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s11060-009-0107-y.pdf

Reference30 articles.

1. Gillam MP, Molitch ME, Lombardi G, Colao A (2006) Advances in the treatment of prolactinomas. Endocr Rev 27(5):485–534

2. Molitch ME (2005) Pharmacologic resistance in prolactinoma patients. Pituitary 8:43–52

3. Wu ZB, Yu CJ, Su ZP, Zhuge QC, Wu JS, Zheng WM (2006) Bromocriptine treatment of invasive giant prolactinomas involving the cavernous sinus: results of a long-term follow up. J Neurosurg 104(1):54–61

4. Wu ZB, Su ZP, Wu JS, Zheng WM, Zhuge QC, Zhong M (2008) Five years follow-up of invasive prolactinomas with special reference to the control of cavernous sinus invasion. Pituitary 11(1):63–70

5. Yu C, Wu Z, Gong J (2005) Combined treatment of invasive giant prolactinomas. Pituitary 8(1):61–65

Cited by 52 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bromocriptine sensitivity in bromocriptine-induced drug-resistant prolactinomas is restored by inhibiting FGF19/FGFR4/PRL;Journal of Endocrinological Investigation;2024-06-26

2. Macroprolactinoma with secondary resistance to dopamine agonists: a case report and review of the literature;Journal of Medical Case Reports;2023-03-17

3. DRD2 expression based on 18F-fallypride PET/MR predicts the dopamine agonist resistance of prolactinomas: a pilot study;Endocrine;2023-01-23

4. Transcriptomic Profiles of Normal Pituitary Cells and Pituitary Neuroendocrine Tumor Cells;Cancers;2022-12-24

5. DRD2 expression based on 18F-fallypride PET/MR predicts the dopamine agonist resistance of prolactinomas: A pilot study;2022-10-28